Exchanges

The View on Flu

Should life companies worry about bird flu? Swiss Re says yes, but Munich Re and a host of primary insurers claim the risks can be overstated. Richard Irving reports

The CRO road

In just over two months all US-based hedge funds with more than 15 investors and/or $25 million under management will have their own dedicated chief compliance officer.

BaFin eases clearing house restrictions

BaFin, the German regulator, has removed a requirement for financial institutions to hold capital against transactions with swaps clearing counterparties – a rule that had threatened German banks' use of SwapClear.

Coping with complexity

The demand for risk-based technology has never been higher due to changing business practices, growing regulatory burdens and burgeoning demand for cross-asset class products. But new entrants can still gain market share in niche areas.

Legal spotlight

Helen Marshall, an attorney at Bingham McCutchen in London, reveals the seven deadly sins of the Market Abuse Directive in the UK

LSE takeover still deadlocked

London Stock Exchange (LSE) management has again rejected Australian bank Macquarie's takeover bid, which was unchanged from the original offer earlier this month.

CSFB launches longevity index

Credit Suisse First Boston released the first-ever longevity index today, which it hopes will enable standardised structuring and settlement of longevity risk transfer instruments such as swaps and structured notes.

NYSE members approve merger

Members at the New York Stock Exchange (NYSE) have voted in favour of the merger with Chicago-based Archipelago today. About 95% of the 1,366 members voted, resulting in a 90% approval rate.

Exchange-traded derivatives up 23% in Q3

The exchange-traded futures and options market has continued its rapid expansion, growing by 23% year-on-year in the third quarter to a turnover of $357 trillion, according to the latest figures released by the Bank for International Settlements (BIS).

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here